Vertex Pharmaceuticals (VRTX) EPS Estimated At $0.71; Ionis Pharmaceuticals (IONS) Shorts Down By 0.26%

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.71 EPS on January, 30.They anticipate $0.39 EPS change or 121.88% from last quarter’s $0.32 EPS. VRTX’s profit would be $181.45 million giving it 62.74 P/E if the $0.71 EPS is correct. After having $0.76 EPS previously, Vertex Pharmaceuticals Incorporated’s analysts see -6.58% EPS growth. The stock increased 1.33% or $2.34 during the last trading session, reaching $178.19. About 167 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 25.22% since January 9, 2018 and is uptrending. It has outperformed by 25.22% the S&P500. Some Historical VRTX News: 04/04/2018 – Q-STATE & VERTEX IN DRUG DISCOVERY PACT FOR OPTOPATCH PLATFORM; 30/05/2018 – S&P ASSIGNS VERTEX AEROSPACE SERVICES CORPORATION OUTLOOK TO ‘POSITIVE’; RATING ‘B’; 01/05/2018 – L3 Signs Definitive Agreement to Sell Its Vertex Aerospace Business to Amer Industrial Partners; 26/04/2018 – VERTEX PHARMACEUTICALS INC QTRLY ADJ SHR $0.76; 26/04/2018 – VERTEX REITERATES 2018 CF PRODUCT REV. GUIDANCE OF $2.65-$2.80B; 26/04/2018 – VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS; 04/05/2018 – STAT Plus: Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’; 01/05/2018 – L3 Signs Definitive Agreement to Sell Its Vertex Aerospace Business for $540 Million in Cash; 11/05/2018 – VERTEX RESOURCE GROUP – LENDERS AGREED TO PROVIDE CO WITH $70 MLN SENIOR SECURED CREDIT FACILITIES FOR A THREE-YEAR TERM; 16/04/2018 – Transformational Tax Executive Michael Davis Joins Vertex

Ionis Pharmaceuticals Inc (NASDAQ:IONS) had a decrease of 0.26% in short interest. IONS’s SI was 12.89M shares in January as released by FINRA. Its down 0.26% from 12.93 million shares previously. With 1.21 million avg volume, 11 days are for Ionis Pharmaceuticals Inc (NASDAQ:IONS)’s short sellers to cover IONS’s short positions. The stock increased 0.69% or $0.39 during the last trading session, reaching $57.2. About 1.21M shares traded or 16.43% up from the average. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has risen 1.50% since January 9, 2018 and is uptrending. It has outperformed by 1.50% the S&P500. Some Historical IONS News: 15/03/2018 – AKCEA THERAPEUTICS INC – CO TO HAVE RIGHTS TO COMMERCIALIZE INOTERSEN AND AKCEA-TTR-L(RX )GLOBALLY; 15/03/2018 – IONIS SEES AKCEA PARTNERSHIP WORTH UP TO $1.7B; 20/04/2018 – Ionis Will Be Responsible for Identification of Antisense Drug Candidates Based on Selected Targets; 15/03/2018 – Ionis Pharma Closes Below 200-Day Moving Average: Technicals; 15/03/2018 – AKCEA THERAPEUTICS INC – TRANSACTION POTENTIALLY WORTH UP TO APPROXIMATELY $1.7 BLN TO IONIS PLUS PROFIT SHARING PAYMENTS; 04/05/2018 – Ionis Pharmaceuticals 1Q Rev $144.4M; 04/05/2018 – IONIS PHARMA 1Q REV. $144.4M, EST. $127.4M; 23/04/2018 – BIOGEN: NEW SPINRAZA DATA UNVEILED AT AAN ANNUAL MEETING SHOW; 10/05/2018 – Akcea, Ionis win over most FDA experts to their rare disease drug volanesorsen, vastly improving odds of success $AKCA $IONS; 16/04/2018 – IONICS INC ION.PS – FY GROSS REVENUE $55.1 MLN VS $50.9 MLN

Among 8 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Vertex Pharmaceuticals had 13 analyst reports since July 26, 2018 according to SRatingsIntel. H.C. Wainwright upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Friday, October 26. H.C. Wainwright has “Buy” rating and $220 target. Citigroup maintained the stock with “Buy” rating in Friday, January 4 report. The company was maintained on Thursday, October 25 by Raymond James. On Thursday, October 25 the stock rating was maintained by BMO Capital Markets with “Outperform”. As per Thursday, July 26, the company rating was maintained by Morgan Stanley. As per Wednesday, December 19, the company rating was maintained by Morgan Stanley. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Market Perform” rating by Raymond James on Wednesday, January 2. Guggenheim maintained the shares of VRTX in report on Tuesday, December 18 with “Neutral” rating. Citigroup maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Monday, July 30. Citigroup has “Buy” rating and $206 target. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 28.

Investors sentiment decreased to 1.06 in 2018 Q3. Its down 0.24, from 1.3 in 2018Q2. It dived, as 42 investors sold Vertex Pharmaceuticals Incorporated shares while 192 reduced holdings. 73 funds opened positions while 176 raised stakes. 231.66 million shares or 2.06% less from 236.55 million shares in 2018Q2 were reported. Bailard holds 0.02% or 2,200 shares. 2,922 were reported by Lourd Capital Lc. Bridgeway Management reported 0.09% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hightower Advsrs Llc reported 10,281 shares or 0.01% of all its holdings. Chevy Chase Tru has invested 0.19% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Spinnaker has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Edgewood Ltd Liability invested 0.02% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Natixis Advsrs L P has 0.21% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ameriprise Incorporated reported 0.39% stake. Bnp Paribas Asset invested in 398,803 shares. Mackenzie Finance reported 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Adirondack Trust holds 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 105 shares. Illinois-based Optimum Advisors has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Macquarie Ltd holds 0.05% or 153,637 shares in its portfolio. Swiss Savings Bank reported 0.17% stake.

Since July 13, 2018, it had 0 insider buys, and 21 insider sales for $12.20 million activity. Another trade for 90 shares valued at $14,738 was sold by Parini Michael. Sachdev Amit sold $2.48 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, July 13. ALTSHULER DAVID had sold 2,125 shares worth $386,516 on Tuesday, August 28. Arbuckle Stuart A sold $377,901 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, November 2. $150,895 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Silva Paul M. The insider Bhatia Sangeeta N. sold 6,818 shares worth $1.31 million. Kewalramani Reshma sold $430,920 worth of stock.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $45.54 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 71.19 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: Nasdaq.com which released: “Ionis Pharmaceuticals Reaches Analyst Target Price – Nasdaq” on January 08, 2019, also Seekingalpha.com with their article: “Ionis Rising On RNA Therapy Optimism – Seeking Alpha” published on December 14, 2018, Seekingalpha.com published: “Ionis: Path To $100 – Seeking Alpha” on December 21, 2018. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: Fool.com and their article: “4 of the Fastest Growing Biotech Stocks in 2019 – The Motley Fool” published on December 31, 2018 as well as Globenewswire.com‘s news article titled: “New Research: Key Drivers of Growth for Baxter International, Sempra Energy, Nielsen Holdings Plc, ARRIS International plc, Ionis Pharmaceuticals, and KB Home — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: December 20, 2018.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company has market cap of $7.87 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.